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Dystrophic epidermolysis bullosa
(DEB) is a congenital inherited blis-
tering disorder caused by mutations in
COL7A1, the gene encoding collagen
VII (COL7), which is a major struc-
tural component of anchoring fibrils
of the hemidesmosome. COL7 protein
comprises a central triple helical
domain flanked by a 145 kDa non-
collagenous amino-terminal domain
(NC1) and a 30 kDa carboxyl-
terminal domain (Burgeson, 1993).
DEB shows either autosomal domi-
nant (DDEB; OMIM#131750) or
recessive (RDEB; OMIM#226600) in-
heritance (Fine et al., 2014). In
contrast, epidermolysis bullosa
acquista (EBA) is a chronic, autoim-
mune, subepidermal blistering skin
disease with circulating IgG anti-
bodies against COL7 (Kim and Kim,
2013). In skin of patients with EBA,
linear deposition of IgG and C3 along
the dermal-epidermal junction (DEJ) is
evident with direct immunofluores-
cence; additionally, indirect immuno-
fluorescence with patient sera shows
linear deposition of IgG along the
dermal side of the DEJ on 1 M NaCl
split skin of normal control in-
dividuals. In most cases of EBA, epi-
topes of the auto-antibodies are
within the NC1 domain of COL7
(Lapiere et al., 1993). Interestingly,
anti-COL7 antibodies can begenerated in patients with RDEB
(Pendaries et al., 2010; Tampoia
et al., 2013; Woodley et al., 2014),
or DEB pruriginosa, which is an
allelic disorder of DDEB
(OMIM#604129) (Jedlickova et al.,
2012). Besides these findings,
whether DEB and EBA can coexist in
a single individual is largely un-
known. Here, we describe a rare case
of DDEB complicated by EBA.
We have seen a three-generation
Japanese family with DDEB at Niigata
University Hospital (Figure 1a). All
three affected individuals in the family
showed blister formations on their
hands and feet during early childhood,
whereas other skin areas and oral mu-
cosa were unaffected. The skin symp-
toms improved with aging and resulted
in scar formation and dystrophic nails
(Figure 1bed). After obtaining institu-
tional approval of experiments and
written informed consent from the pa-
tients, we performed direct sequencing
analysis and identified a recurrent
heterozygous missense mutation
c.7868G>A (p.Gly2623Asp) in the
COL7A1 gene of all three affected in-
dividuals (Supplementary Materials and
Methods online) (Figure 1e). On the
basis of previous reports of DDEB with
the identical mutation (Varki et al.,
2007) or other missense mutations at
the amino acid position 2623
(Christiano et al., 1995; Sawamuraet al., 2006; Varki et al., 2007), we
expected a good prognosis for the
affected individuals in this family.
To our surprise, however, the eldest
patient in the family (I-1; Figure 1a)
eventually showed bullae and subse-
quent scar formation all over her body,
including oral mucosa at the age of 63
(Figure 1feh). Skin biopsy from her left
arm revealed subepidermal bulla for-
mation with dense infiltration of lym-
phocytes, eosinophils, and neutrophils
(Figure 1i). Although circulating auto-
antibodies against the NC16a domain
of 180 kDa bullous pemphigoid antigen
were not evident in blood test, we
postulated that she might suffer from an
autoimmune blistering disease. To test
this hypothesis, we conducted a series
of analyses with samples of this pa-
tient’s skin and serum (Supplementary
Materials and Methods). Direct immu-
nofluorescence with skin sections from
this patient revealed linear deposition
of IgG and C3 at the DEJ (Figure 1j; data
not shown). In addition, indirect
immunofluorescence with 1 M NaCl
split normal human skin sections and
the patient’s serum clearly demon-
strated linear deposition of IgG at the
dermal side of the DEJ (Figure 1k),
suggesting that the antigen recognized
by the auto-antibodies localized below
the lamina lucida. Strikingly, Western
blot analysis with the patient’s serum
showed a 290 kDa fragment in dermal
extracts from a control individual,
which corresponded to the molecular
weight of COL7 (Figure 2a). By
contrast, the patient’s serum did not
recognize any component of laminin
Figure 1. Clinical features of a Japanese family with dominant dystrophic epidermolysis bullosa (DDEB), in which one patient developed an autoimmune
blistering disease. (a) Pedigree of the family. The affected individuals are colored in black. (bed) Clinical features of the family members with DDEB. (e)
Identification of a heterozygous missense mutation c.7868G>A (p.Gly2623Asp) in the COL7A1 gene of the affected family members. (feh) Clinical features of
patient I-1 at age 63. She exhibited blistering formations on the oral mucosa (f) and all over her body (g, h) with scars and erosions. (i) Hematoxylin and eosin
staining of a skin biopsy from patient I-1. Magnification: 200. (j) Direct immunofluorescence with skin sections from patient I-1. (k) Indirect
immunofluorescence using 1 M NaCl split normal human skin sections and serum from patient I-1. Scale bars ¼ 100 mm (j), 50 mm (k).
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bility of mucous membrane pemphi-
goid (Figure 2b). We also confirmed
that COL7 protein was expressed in the
patient’s skin, although the expression
looked slightly weaker than that in
normal human skin (Supplementary
Figure S1 online). To determine the
domain of epitopes for the anti-COL7
auto-antibodies circulating in this pa-
tient, we overexpressed either the NC1
domain or the remaining domains of
COL7 with a Flag tag in HEK293T cells,
purified them with an anti-Flag anti-
body (Figure 2c), and performedWestern blot using sera from the patient
or a healthy control individual
(Figure 2d); this analysis revealed that
the patient’s serum specifically reacted
with the NC1 domain of COL7
(Figure 2d). Furthermore, a reactive
oxygen species production assay
showed that the patient’s serum signif-
icantly activated normal human neu-
trophils (Figure 2e). On the basis of
these results, we concluded that the
auto-antibodies against the NC1
domain of COL7 caused EBA in the
patient. For the treatment of EBA,
administration of oral prednisolone (0.5mg/kg daily) was started; however, the
efficacy of this treatment was limited.
The patient showed severe hypo-
albuminemia and anemia; she ulti-
mately died at the age of 66.
In this report, we present a female
Japanese patient who had symptom-
atic, congenital DDEB as a child
and developed EBA later in her life.
The COL7A1 mutation identified in
the patient was a glycine substitu-
tion within the central triple helical
domain of COL7, and the mutant COL7
protein was predicted to moderately
inhibit triplehelix formationofwild-typewww.jidonline.org 321
Figure 2. Detection of auto-antibodies against the NC1 domain of collagen VII (COL7). (a) Western blots (WB) using dermal extracts. Serum from patient I-1
recognized a 290 kDa fragment (lane 1; arrow), as did serum from a different patient with epidermolysis bullosa aquisita (EBA) (lane 2; arrowhead).
Serum of a patient with anti-p200 pemphigoid showed a 200 kDa fragment (lane 3; arrowhead). (b) WB using purified laminin 332. Positive fragments are
indicated by arrowheads. MMP, mucous membrane pemphigoid. (c) Flag-tagged COL7 proteins (Flag-COL7-NC1 and Flag-COL7-NC1 (e)) were purified by
immunoprecipitation (IP), and were verified by WB. (d) WB with sera from patient I-1 (Pt) or a healthy control individual (C). (e) Reactive oxygen species (ROS)
production by neutrophils was stimulated by incubation of the patient’s serum with human COL7; phorbor myristate acetate (PMA) was used as positive control.
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Supplementary material is linked to the online
version of the paper at www.jidonline.org, and at
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this effect presumably resulted in
aberrant anchoring fibrils and caused a
mild form of DDEB (Figure 1bed).
Because previously reported cases
of patients with RDEB with circulat-
ing anti-COL7 antibodies were not
complicated by EBA (Pendaries et al.,
2010; Tampoia et al., 2013; Woodley
et al., 2014), not only the COL7A1
mutation but also genetic modifiers
and/or environmental factors might be
involved in pathogenesis of EBA in our
patient.
To date, only one case of DEB pruri-
ginosa has been reported to have
circulating anti-COL7 antibodies and
cause EBA, whereas neither direct
immunofluorescence nor indirect
immunofluorescence showed IgG
deposition at the DEJ (Jedlickova et al.,
2012). Therefore, our findings provided
more reliable evidence that anti-COL7Journal of Investigative Dermatology (2016), Volumauto-antibodies generated in a patient
with DDEB could induce EBA; they also
indicated that COL7A1 mutations may
be a risk factor of EBA in some cases.
Nevertheless, the exact mechanisms
responsible for EBA development in
DDEB and establishment of ideal
treatments for such a rare condition
await further studies.
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A high prevalence of psoriasis has been
reported in Norway, ranging from 4.8%
to 11.8% (Bo et al., 2008; Danielsen
et al., 2013; Kavli et al., 1985; Parisi
et al., 2013). Prevalence estimates
depend crucially on the validity of
questionnaires (Jagou et al., 2006; Kurd
and Gelfand, 2009; Lima et al., 2013;
Plunkett et al., 1999; Rea et al., 1976;
Wolkenstein et al., 2009). We aimed
to validate self-reported psoriasis in
a large population-based study in
Norway using clinical skin examination
performed by dermatologists as the
gold standard and also to estimate
the validation-based prevalence of
psoriasis in a general Norwegian
population.
Among adult participants of the third
survey of the Nord-Trøndelag Health
Study (HUNT3, 2006e8) (Krokstad
et al., 2013), we invited random sam-
ples of 150 with and 700 without self-
reported psoriasis, of whom 110 and
434 participated in the validation study,
respectively (see Supplementary
Figure S1 online). Validation was done
by comparing the result of the self-
reported question “Have you had or
do you have psoriasis?” in HUNT3 to
the outcome of the clinical interview
and extensive skin examination per-
formed by three dermatologists (EHM,IS, and MS). Because the diagnosis is
based on clinical signs and symptoms
(Boehncke and Schon, 2015), psoriasis
was defined as having a positive
history in combination with clinical
findings present at the day of skin ex-
amination. In cases of complete remis-
sion on examination day, diagnostic
confirmation had to be obtained either
from a previous medical record
collected from a dermatological clinic
or by a former skin biopsy. To obtain
estimates representative for the total
HUNT3 population, appropriate weights
were applied to account for differ-
ences in sampling probability. An
age-standardized prevalence estimate
according to the European standard
population distribution for adults > 20
years was calculated (Pace et al., 2013)
(see Supplementary Materials and
Methods online).
General characteristics of the 544
participants did not differ substantially
from the total HUNT3 study population
or from the nonresponders (see
Supplementary Tables S1 and S2 on-
line). Compared with all people with
self-report of psoriasis in HUNT3, par-
ticipants in the validation study re-
ported essentially similar characteristics
of their psoriasis but slightly more often
nail changes, psoriasis arthritis, and
having the diagnosis confirmed by adermatologist (see Supplementary
Table S3 online).
The overall self-reported prevalence
of psoriasis in HUNT3 was 5.8% (95%
confidence interval [CI], 5.6e6.0%),
and the validated prevalence was esti-
mated to 8.0% (95% CI, 6.4e9.9%)
(Table 1). Self-reported psoriasis had an
estimated sensitivity of 56% (95% CI,
44e68%), a specificity of 99% (95%
CI, 98e99%), a positive predictive
value of 78% (95% CI, 69e85%), and a
negative predictive value of 96% (95%
CI, 94e98%) (Table 2). The positive
predictive value increased to 84% if the
psoriasis question was combined with
the additional question, “Have you
been diagnosed with psoriasis by a
dermatologist?”
Four participants diagnosed with
psoriasis in the period between the
HUNT3 and the validation study were
classified as true negatives. True-
positive participants (n ¼ 86) had a
mean psoriasis area and severity index
of 2.9, whereas false-negative partici-
pants (n ¼ 16) had a mean psoriasis
area and severity index of 0.9. Among
false-negative participants, most had
scalp psoriasis only (n ¼ 12). The group
of false positives (n ¼ 24) consisted of
subjects whose history of psoriasis
could not be verified by a dermatologist
or pathologist (n ¼ 10); people with
unspecified dermatitis (n ¼ 5), benign
skin tumors (n ¼ 2), and urticaria
(n ¼ 1); and 6 individuals without any
history of psoriasis or other relevantwww.jidonline.org 323
